- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Naiyer A. Rizvi, MD | Authors
Articles
Activity and Toxicity of Pembrolizumab for NSCLC
July 10, 2014
Video
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).
Pseudoprogression in Lung Cancer after Immunotherapy Treatment
December 03, 2013
Video
Naiyer A. Rizvi, MD, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.
Advertisement
Advertisement